Vincerx Pharma Inc. has received IND clearance from the FDA to initiate a phase I trial for VIP-943, an antibody-drug conjugate (ADC) for acute myeloid leukemia (AML). The study, which will involve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback